Walleye Capital
ONCT

Walleye Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Walleye Capital’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,011
Closed -$91K – 2702
2021
Q4 		$91K Buy
+2,011
New +$135K ﹤0.01% 1707

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's ONCT Position: Q1 2022 in Review

Walleye Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2022, closing a stake of 2,011 shares — an estimated $91K sold.

Walleye Capital first reported a position in ONCT in Q4 2021 and held it in 1 quarter. The position peaked at $91K in Q4 2021. 78 funds tracked by Wall St. Rank hold ONCT as of Q1 2022.

  • Walleye Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Walleye Capital sold 2,011 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $91K.
  • Walleye Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Walleye Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $91K in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.